International Conference on Lung Diseases and Care September 24-25, 2020 Paris, France

COPD:

COPD is a disease that involves inflammation and thickening of the airways. It additionally includes pulverization of the tissue of the lung where oxygen is traded. It is described by the Global Initiative for Chronic Obstructive Lung Disease as “a preventable and treatable disease. Portrayed via wind current impediment that isn't completely reversible. The wind current constraint is typically dynamic and related with an unusual fiery reaction of the lung to poisonous particles or gases. This progressive and relentless loss of Lung Diseases is caused by emphysema due to destruction of lung parenchyma. Smoking (long term smokers), Chronic bronchitis, Inherited factors (genes) and by narrowing of small airways as a result of chronic inflammation and Fibrosis and loss of elastic recoil. This outcomes in dynamic wind stream impediment, air catching, and dynamic brevity of Breath on effort.

Immunotherapy, Chemotherapy and Radiotherapy for Lung Cancer:

At the point when different treatments are incapable, immunotherapy may offer critical advantage to lung malignant growth patients. Immunotherapy utilizes materials made inside body or in a research facility to help the body's regular guard framework against tumor cells. The immunotherapy drugs, nivolumab (Opdivo) and pembrolizumab (Keytruda) are checkpoint inhibitors that focus on the PD-1 protein, which fortifies the insusceptible reaction against the malignancies. Atezolizumab (Tecentriq) is a medication that objectives PD-L1, a protein identified with PD-1 that is found on some tumor cells and invulnerable cells. A better understanding of the role of immune checkpoints in the cancer immunity cycle and advancements in computational and bioinformatics platforms enabled the development of cancer neoantigen vaccination strategies.

Depending on the type of tumor, chemotherapy is used as the first-line treatment in both SCLC and NSCLC. Cisplatin and etopside are used along with radiation to treat early stage small cell lung carcinoma. They are also used in combination of carboplatin, gemcitabine, paclitaxel, vinorelbine, topotecan, and irinotecan. While in advanced non-small cell lung carcinoma, cisplatin and carboplatin are used to improve survival rates along with gemcitabine, paclitaxel, docetaxel, pemetrexed, etoposide and vinorelbine.

Radiotherapy is often accompanied with chemotherapy to people with NSCLC who are ineligible for surgery. Consistent high fractionated quickened radiotherapy (CHART) is prescribed for individuals with NSCLC while chest radiotherapy is suggested for individuals with reparable SCLC notwithstanding chemotherapy. Palliative radiotherapy to the chest is applied to both patients of NSCLC and SCLC to control the symptoms. With the assistance of focusing on and imaging innovations, stereotactic radiation is utilized to treat beginning period lung disease.

Lung Cancer Surgery and Transplantation:

Even after careful selection, considering the stage, location and cell type of the cancer, the operative death rate of lung cancer surgery is about 4.4%. Hence surgery is only suitable for NSCLC stages 1A, 1B, 2A and 2B. In thoracotomy, the surgeon generally opens up the chest cavity by making an incision in the side of the chest and by spreading apart the ribs to gain access to the cancerous tissues.

A lung transplant expels an individual's diseased lung and replaces it with a healthy one. The healthy lung originates from a benefactor who has died. Lung transplants are utilized for individuals who are probably going to die from lung diseases within 1 to 2 years. Their conditions are severe to different medications, for example, drugs or breathing gadgets, no longer work. Lung transplants regularly are utilized to treat individuals who have serious COPD, Cystic fibrosis, Idiopathic pulmonary fibrosis, Alpha-1 antitrypsin inadequacy and pulmonary hypertension.

Lung Diseases and Respiratory Health:

Lung illness ranges from bronchitis and pneumonia to aspiratory hypertension. Lung function tests and X-rays are used to diagnosis the problem. Many symptoms can be eased with proper treatment. If not treated they may directly or indirectly lead to lung cancer.

Awareness and Prevention of Lung Cancer:

Lung disease can once in a while be recognized in its most punctual stages, when treatment is bound to bring about a fix. When side effects show up, it's frequently past the point of no return for therapeudic medical procedure, leaving just medications that mean to improve personal satisfaction. In spite of the fact that analysts have gained noteworthy ground in chemotherapy for all phases of infection, a great many people determined to have symptomatic lung malignant growth don't endure. In the course of recent years, the U.S. has seen an empowering decrease in the commonness of smoking, through forceful enemy of tobacco crusades and strategies. Be that as it may, this decrease currently has all the earmarks of being easing back, while an inadmissibly enormous populace is in danger from lung malignancy. Lung malignant growth is answerable for almost 30 percent of all disease passings every year — more than that of bosom disease, prostate malignancy and colon malignancy joined. As the prime reason for malignancy related passings in the country, lung disease gets awfully little consideration.

Pulmonary Hypertension and Therapeutics:

Advanced diagnostic techniques such as X-ray and echocardiography is used to diagnose lung diseases and lung function tests is another test to determine lung cancer disease. This is a medical process involving the pleural cavity and other thoracic internal examination, biopsy and resection of the disease or mass. Thoracoscopy may be sedation under general anesthesia or local anesthesia. Surgical biopsy is a better way to diagnose lung cancer standards. Must wear appropriate masks & monitor exposure and in some working environments it is important to take precautions. Chronic obstructive pulmonary disease is a gradual process that causes difficulties in the death of respiratory failure or its associated lung disease and is the process of stopping smoking.

Occupational & Environmental lung Disease:

Occupational & Environmental lung diseases are group of diseases caused by the inhalation of dust, chemicals, or proteins. The severity of the disease is identified with the material inhaled and the intensity of exposure.

Some of the Occupational Lung diseases are Asthma, Bronchiolitis Obliterans, COPD, Hypersensitivity Pneumonitis, Lung Cancer, Mesothelioma, Pneumoconiosis.

Some of the Environmental lung diseases caused by Arsenic, Asbestos, BCME, Beryllium, Cadmium, Chromium, Coal dust, Diesel exhaust, Indium lung, Nickel, Silica and Tobacco smoke etc

Prevention and control of lung disorders:

As per market standards we have advanced diagnostic techniques like X-Ray and Echocardiogram are to diagnose and identify Lung cancer and Pulmonary Function Testing (PFT) is another test to identify lung cancer disease. This is a therapeutic procedure including for this inward assessment, biopsy and resection of malady or masses inside the pleural cavity and other thoracic cavity. Thoracoscopy might be act either under general anesthesia or sedation with neighborhood soporific.Surgical biopsy was the standard better way to diagnose of Lung cancer. We need to wear proper covers and observing presentation to investigating in certain workplaces are significant safety measures to pursue. COPD a progressive course causing death from Respiratory failure or difficulties from its associated Lung diseases, which include Respiratory Artery Disease, lung cancer, stroke and Smoking Cessation, is the process of discontinuing tobacco smoking. Tobacco contains nicotine, which is addictive; during the way toward stopping very expanding and troublesome we can control with immunization and aversion fix.

Tobacco Smoking:

Respiratory disorders are very most common medical conditions diseases in the world. Some of millions individuals enduring with lung ailment in the U.S. Smoking and contaminations, Lung issue are answerable for all lung sicknesses. The lungs are a piece of human body and it growing and loosening up a large number of times air every day to get oxygen and discharging carbon dioxide. Aspiratory Disease can distinguish in any piece of this Respiratory framework. The trachea into cylinders called bronchi, which thusly branch to decrease tubes in to the lungs.

Asthma and allergy:

Allergy occurs when the immune system in an individual responds to allergens which are substances in condition that don't cause issues for many people. This response prompts irritation (redness and swelling) that causes unfavourably susceptible conditions, which can influence different parts  of the body, for example, hypersensitive rhinitis, skin inflammation or urticaria, hypersensitivity and asthma.

Individuals with asthma experience a narrowing of the airway routes in the lungs, which obstructs the stream of air into and out of the lungs.

The global Lung care market is estimated to currently be worth $11.3 billion, and is forecast to reach

a value of $15.6 billion by 2019. The drugs driving this growth include once-daily LABA/LAMA

fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium.

The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein.

North America leads the global market for asthma &COPD drugs and devices. North America was followed by Europe in terms of market capitalization. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.

The current asthma and COPD market is primarily driven by increasing patient population. It is also growing due to factors such as price erosion and expiry of patents of leading drug brands in the market. However, it is estimated that in the next five years, the global asthma and COPD drug market is expected to grow slowly and steadfast. The COPD segment was projected to be worth USD 10,593.2 million and is expected to reach USD 12,619.8 million in 2017.

In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment.

Top few companies in this global market:

AstraZeneca

GlaxoSmithKline

F. Hoffmann-La Roche

Novartis and Merck

Abbott

Amgen

Actavis

Boehringer Ingelheim

Cipla

Glenmark

Pfizer

Ranbaxy

Sunovion

Vectura

Global COPD & Asthma Devices Market, By Product:

Inhalers

Nebulizers

Inhalers accounted for the major market and is expected to continue its dominance till 2020

Global COPD & Asthma Devices Market, By Geography

North America

Europe

Asia-Pacific

LAMEA

LAMEA region would exhibit the highest CAGR of 4.9% during 2017-2020

Major COPD Research Associations around Asia Pacific:

COPD Patient Organization of Vietnam

COPD Patients Club Kyrgyzstan

COPD Club of Northern Thailand

Asian Pacific Society of Respirology

Chinese COPD Patient Education Organziation

Major COPD Research Associations around Globe

Alpha-1 Foundation

American Association for Respiratory Care

American College of Chest Physicians

American College of Emergency Physicians

American College of Physicians

American Lung Association

Canadian Lung Association (CLA)

COPD Foundation

Target Audience:

• Directors, Board Members, Presidents, Vice Presidents, Deans and Head of the Departments

• COPD Students, Scientists, Faculty

• Medical Colleges

• COPD Associations and Societies

• Business Entrepreneurs, Pharmaceutical companies

Universities Associated:

Major Universities on COPD Research

Kumamoto University, Japan

Tokyo National Hospital, Japan

KindaiUniversity, Japan

Okayama University, Japan

Medi7 Bentleigh, Australia

Macquarie University, Australia

Australian national university, Australia

Charles Darwin University Casoria Australia

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Iqbal Chest Centre, Bangladesh

Imperial College London, United Kingdom

Linnaeus University, Sweden

University Of California Los Angeles, United States

Columbia University Medical Center, United States

Harvard University, United States

Lung Care 2020

CONFERENCE AWARD PAGE

Meetings International has always been at the forefront to support and encourage the scientific and techno researchers to march forward with their research work. Lung Care 2020 offers various awards as reorganization to exceptional researcher and their research work. We invite all enthusiastic researchers from all around the world join us for the International Conference on Lung Diseases and Care scheduled in Paris, France on September 24-25, 2020.

Eminent Key Note Speaker Award:

Lung Care 2020 will confer the Model Key Note Speaker Award to the researchers who have spent a considerable time of their academic life towards the research related to conference topic. Key note speaker award is for the researchers/speakers who have done all the hard work behind the scene. It will be a small clap for their dedication and hard work.

Outstanding Speaker Award:

Lung Care 2020 will bestow model speaker award to those researchers who have made significant contribution towards the conference topic during their research period as well as presented the research topic in an impressive way in the oral presentation during the summit. It will be an apt appreciation from the Jury as well as from the delegates. The award they receive will motivate them to march forward with the research work.

Model Organizing Committee Member Award:

Lung Care 2020 will take this opportunity to facilitate eminent experts from this field with the model Organizing Committee Member award for their phenomenal contribution towards the society through their academic research. This will be a trivial but significant reorganization of their dedication and discipline.

Promising Young Researcher Award:

The motive of this Award during the Lung Care 2020 is to appreciate research work of the budding young researcher who is continuing their research work to create a better society. The award will provide them a tremendous amount of encouragement to keep moving forward.

Educative Poster Award:

The educative poster award for the Lung Care 2020 will be endorsement for those who wishes to display their research paper through a poster and will act as a guiding force those researchers. The award will be presented to the most informative and educative research poster.

Criteria:

All presented abstracts will automatically be considered for the Award.

All the presentation will be evaluated in the conference venue.

All the awards will be selected by the judges of the award category.

The winners will be formally announced during the closing ceremony.

The winners of the Poster Award will receive award certificate.

The awards will be assessed as far as plan and format, intelligence, argumentation and  approach, familiarity with past work, engaging quality, message and primary concerns, parity of content visuals, and by and large impression.

Guidelines:

All submissions must be in English.

The topic must fit into scientific sessions of the conference.

Each individual participant is allowed to submit maximum 2 papers.

Abstract must be submitted online as per the given abstract template.

Abstracts must be written in Times New Roman and font size will be 12.

Abstract must contain title, name, affiliation, country, speaker’s biography, recent photograph, image and reference.

Each poster should be approximately 1x1 M long. The title, contents and the author’s information should be clearly visible from a distance of 1-2 feet.